We recently published 10 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks that’s on Jim Cramer’s radar.
Shares of pharmaceutical giant Johnson & Johnson (NYSE:JNJ) are up 53% over the past year and 15% so far this year. In recent months, Cramer has become optimistic about the company. Some factors that have driven his opinion include Johnson & Johnson’s (NYSE:JNJ) cancer drug portfolio and its orthopedic spin-off product. Recently, RBC Capital raised its price target on shares of Johnson & Johnson (NYSE:JNJ) to $255 from $240 and maintained an Outperform rating on the stock. The bank noted that the pharmaceutical company had solid finances to deal with its legal problems. Like RBC, Bank of America also raised its price target on Johnson & Johnson (NYSE:JNJ) stock. He raised the target to $227 from $221 and maintained a Neutral rating on the stock. According to BofA, the company’s organic growth was leading to healthier multiples. Johnson & Johnson (NYSE:JNJ)’s annual revenue in 2025 grew 6% to $94.2 billion, while the company outlined that revenue could reach $100.5 billion in 2026. Cramer remains enamored of the pharmaceutical company, as he briefly commented:
Trong Nguyen / Shutterstock.com
“JNJ is amazing.”
While we recognize JNJ’s potential as an investment, our conviction lies in the belief that some AI stocks have more promise to generate higher returns and have limited downside risk. If you’re looking for an extremely cheap AI stock that’s also one of the biggest beneficiaries of Trump’s tariffs and offshoring, check out our free report on the best short-term AI stock.
READ NEXT: 30 stocks that should double in 3 years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published in Internal jumpsuit.